InflaRx N.V.
NASDAQ:IFRXBiotechnology
-$0.02 today
- Market cap
- $163.58M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
Volume 3.05M
Average 1.80M
IFRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
InflaRx N.V.NASDAQ: IFRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of €4.17M fell 40.6% year over year, behind the -34.8% change in trailing-twelve-month research & development. Sequentially, it fell 20.7% from the prior quarter. Over 3 fiscal years it compounded at -11.8% a year.
Context
- Research & development amounted to 87691.5% of revenue in FY2025, up 66360.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -40.6% toward the trailing-twelve-month pace of -34.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 25.72M EUR
- Year-over-year change
- -27.3%
- 4-year CAGR
- -7.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.72M | -27.3% |
| FY2024 | 2024-12-31 | 35.36M | -13.8% |
| FY2023 | 2023-12-31 | 41.02M | +9.3% |
| FY2022 | 2022-12-31 | 37.53M | +5.1% |
| FY2021 | 2021-12-31 | 35.7M | — |
Research & Development vs competitors
How IFRX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -34.8% is the 7th highest of 9, against a peer median of +14.4%.
- Research & development amounts to 77989.1% of revenue for IFRX, versus a peer median of 16478.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.37M USD | -38.7% | +6.7% | 152.0% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $71.8M USD | +27.7% | +16.5% | — |
| LTM Mar 2026 | $55.72M USD | +5.5% | +12.0% | 29327.4% | |
| FY2025 | $37.8M USD | +29.2% | -26.9% | 59059.4% | |
| LTM Mar 2026 | $36.3M USD | -40.4% | -24.8% | 3629.9% | |
| LTM Mar 2026 | $35.41M USD | +46.4% | +65.0% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $32.3M USD | -29.1% | +37.8% | — |
IMAImageneBio Inc | LTM Mar 2026 | $30.77M USD | +23.4% | -23.7% | — |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| Peer median (excluding IFRX) | — | +14.4% | +9.4% | 16478.6% | |
Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 63.09K | 165.79K | 29.33K |
| Cost of Revenue | 0 | 0 | 532.26K | 3.32M | 7.27M |
| Gross Profit | 0 | 0 | (469.17K) | (3.15M) | (7.24M) |
| Gross Margin | — | — | -743.7% | -1900.8% | -24677.9% |
| Research & Development | 35.7M | 37.53M | 41.02M | 35.36M | 25.72M |
| Selling, General & Admin | 11.43M | 14.34M | 16.12M | 19.33M | 17.56M |
| Operating Expenses | 47.63M | 32.24M | 44.13M | 49.75M | 41.02M |
| Depreciation & Amortization | 669.43K | 596.6K | 567.78K | 485.11K | 419.48K |
| EBITDA | (44.94M) | (28.84M) | (42.06M) | (45.55M) | (45.16M) |
| EBITDA Margin | — | — | -66674.3% | -27476.7% | -153976.3% |
| Operating Income | (47.63M) | (32.24M) | (44.59M) | (52.91M) | (48.26M) |
| Operating Margin | — | — | -70685.6% | -31911.4% | -164525.5% |
| Interest Income | 109.39K | 608.68K | 3.8M | 3.2M | 1.77M |
| Interest Expense | 24.77K | 45.25K | 35.63K | 20.66K | 37.69K |
| Other Income / Expenses | 2M | 2.75M | 1.93M | 6.85M | 2.64M |
| Income Before Tax | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (45.62M) |
| Pre-Tax Margin | — | — | -67630.7% | -27781.8% | -155540.2% |
| Income Tax Expense | 0 | 0 | 0 | 5.22K | 12.28K |
| Net Income | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (45.63M) |
| Net Margin | — | — | -67630.7% | -27785.0% | -155582.1% |
| EPS (Basic) | (1.10) | (0.61) | (0.78) | (0.78) | (0.66) |
| EPS (Diluted) | (1.10) | (0.61) | (0.78) | (0.78) | (0.66) |
| Weighted Avg Shares | 41.63M | 44.21M | 54.94M | 58.92M | 67.29M |
| Weighted Avg Shares (Diluted) | 41.63M | 44.21M | 54.94M | 58.92M | 67.29M |
InflaRx N.V.
NASDAQ:IFRX
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.